The findings address a major clinical problem. Patients who develop acute kidney injury together with acute lung injury face a substantially higher risk of respiratory failure and death than patients with injury to either organ alone. The connection is not simply a consequence of fluid accumulation or reduced kidney function. Damaged kidneys can release inflammatory mediators, danger signals and cellular debris into the circulation, activating immune cells and the vascular lining throughout the body. In the lungs, this systemic response can weaken the alveolar–capillary barrier, allowing fluid and inflammatory cells to enter air spaces that are normally reserved for gas exchange.

Ischemia–reperfusion is a particularly powerful trigger for this kind of secondary injury. During a period of insufficient blood supply, kidney cells experience oxygen and energy deprivation. The sudden return of oxygenated blood, although essential for tissue survival, can generate reactive oxygen species and amplify mitochondrial stress. Injured cells release damage-associated molecular patterns, or DAMPs, which alert the innate immune system to tissue damage even in the absence of an infection. HMGB1 is one of the best-known DAMPs. Normally located in the cell nucleus, where it helps organize DNA, HMGB1 can move outside the cell after injury or active secretion and function as a potent inflammatory signal.

Extracellular HMGB1 can bind receptors such as toll-like receptors and the receptor for advanced glycation end products, initiating signaling cascades that activate nuclear factor kappa B and other inflammatory programs. These pathways can increase the production of cytokines, chemokines and adhesion molecules, encouraging immune cells to migrate into vulnerable tissues. In the lung, such signaling may promote endothelial and epithelial dysfunction, disturb fluid regulation and impair the surfactant-dependent mechanics required to keep alveoli open. The study by Ning, Kuai, Zhou and colleagues places MYH9 within this injury network, suggesting that HMGB1 does more than transmit an inflammatory message from the kidney.

MYH9 encodes non-muscle myosin IIA, a motor protein involved in actin-based cellular movement, shape changes, adhesion and barrier organization. Although myosin proteins are often associated with muscle contraction, non-muscle myosin IIA is active in many cell types, including endothelial and epithelial cells. It helps cells maintain mechanical integrity and respond to external signals. The reported HMGB1/MYH9 relationship therefore offers a potential explanation for how an inflammatory molecule can produce structural and functional changes in lung tissue. By influencing MYH9-associated signaling or cellular architecture, HMGB1 may help destabilize the pulmonary barrier while also altering gene regulation.

At the center of the proposed mechanism is PPARγ, a ligand-activated transcription factor that regulates lipid metabolism, inflammation and cellular differentiation. PPARγ is expressed in several lung cell populations and has been associated with maintenance of epithelial function and restraint of excessive inflammatory responses. When activated, it can oppose pro-inflammatory transcriptional programs and influence the expression of genes involved in oxidative stress, immune signaling and tissue repair. The study’s central claim is that HMGB1, acting through or in association with MYH9, suppresses PPARγ during renal ischemia–reperfusion, removing an important brake on lung inflammation.

That mechanism also provides a rationale for examining rosiglitazone. The drug belongs to the thiazolidinedione class and is a synthetic agonist of PPARγ. By binding the receptor, rosiglitazone can promote PPARγ-dependent transcription and potentially restore protective gene activity that has been reduced during systemic injury. In the context described by the researchers, treatment with rosiglitazone produced protective effects against lung injury following renal ischemia–reperfusion. The implication is not that the drug simply reduces inflammation in a nonspecific way, but that it may act downstream of the HMGB1/MYH9 pathway by reactivating a transcriptional program capable of preserving pulmonary tissue.

The work is important because it links three biological levels that are often studied separately: the release of an injury alarm signal from the kidney, the activity of a cytoskeletal and signaling protein, and the suppression of a nuclear receptor that helps regulate lung homeostasis. Such a chain could offer new biomarker opportunities. Elevated HMGB1 might indicate active systemic tissue damage, while changes involving MYH9 or PPARγ could provide information about the likelihood or severity of secondary lung injury. However, biomarkers must be validated in human patients, since concentrations measured in experimental models may not directly predict clinical outcomes.

The therapeutic implications are promising but require careful interpretation. Rosiglitazone is already known to have clinically important adverse effects, including fluid retention and cardiovascular concerns in susceptible patients. Those risks are especially relevant in people with kidney injury, who may already be vulnerable to altered fluid balance and cardiac stress. A treatment that activates PPARγ could also affect metabolism and immune responses in ways that differ between children and adults. The findings therefore support further investigation of PPARγ-centered therapies, but they do not establish rosiglitazone as a ready-to-use treatment for patients with acute kidney–lung injury.

The study ultimately reinforces the view that organ failure is often a network disease rather than an isolated local event. A kidney deprived of blood and then reperfused can initiate molecular signals that reshape the behavior of distant organs, with HMGB1/MYH9-mediated suppression of PPARγ emerging as a possible driver of pulmonary damage. If future work confirms the pathway in human tissue and clarifies which cells are most responsible, clinicians may be able to identify patients at risk before respiratory deterioration becomes severe. The findings from Ning, Kuai, Zhou and colleagues offer a mechanistic lead for that effort and suggest that restoring endogenous anti-inflammatory programs may be as important as blocking inflammatory signals themselves.

Subject of Research: The role of HMGB1/MYH9-mediated suppression of PPARγ in lung injury caused by renal ischemia–reperfusion, and the protective potential of rosiglitazone.

Article Title: HMGB1/MYH9 suppresses PPARγ to induce lung injury in renal ischemia-reperfusion: protective effects of Rosiglitazone

Article References: Ning, D., Kuai, Y., Zhou, Y. et al. HMGB1/MYH9 suppresses PPARγ to induce lung injury in renal ischemia-reperfusion: protective effects of Rosiglitazone. Pediatric Research (2026). https://doi.org/10.1038/s41390-026-05346-0

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05346-0

Keywords: acute kidney injury, acute lung injury, renal ischemia–reperfusion, HMGB1, MYH9, PPARγ, rosiglitazone, inflammation, organ crosstalk, biomarkers

To understand the significance of this research, we first need to look at what heart failure and preserved ejection fraction (HFpEF) entail. HFpEF is characterized by the heart’s inability to pump effectively despite normal left ventricular ejection fraction. This condition affects a significant portion of the elderly population and is frequently accompanied by comorbidities such as hypertension and obesity. As the incidence of HFpEF continues to rise, the search for reliable prognostic markers becomes increasingly urgent.

The study comments on the SII, which encapsulates a patient’s systemic inflammatory response by combining lymphocyte and platelet counts with fibrinogen levels. This index reflects the balance between the immune system and inflammation status in the body, making it an innovative tool in assessing the severity of various diseases, particularly those involving complex pathophysiological mechanisms like heart failure. The researchers argue that higher SII levels correlate strongly with poorer outcomes in HFpEF patients, suggesting its potential role as a predictive marker in clinical settings.

Cardiovascular diseases have been the leading cause of death globally, and with heart failure’s increasing prevalence, innovative approaches are imperative. The research implicates SII as not only a predictive marker but also a potential therapeutic target. By elucidating the inflammatory pathways involved in HFpEF, clinicians can tailor treatment strategies more effectively, focusing on the underlying inflammation that often accompanies heart failure.

One of the critical takeaways from the commentary is the awareness of immune responses within the cardiovascular system. The intricate interplay between the immune system and cardiovascular health cannot be overstressed. Chronic inflammation is known to contribute significantly to the pathogenesis of heart failure, and thus, recognizing the role of biomarkers like SII is vital. As a result, this research paves the way for future therapeutic avenues that may include anti-inflammatory strategies aimed at mitigating heart failure progression.

In addition to the clinical implications, this commentary emphasizes the importance of utilizing accessible metrics like the systemic immune-inflammation index in everyday practice. Assessing SII could allow practitioners to identify at-risk patients sooner, enabling earlier interventions that could shift the trajectory of heart failure outcomes. The research underscores the growing need for awareness among healthcare providers regarding the inflammatory dimensions of diseases.

Moreover, it is essential to consider the potential influence of lifestyle factors on SII and heart failure. Conditions such as obesity and sedentary lifestyles have been shown to exacerbate systemic inflammation. Therefore, addressing these concerns at a community health level, along with clinical adjustments, could create a multi-faceted approach that tackles heart failure from various angles.

As the dialogue around heart failure and systemic inflammation develops, it is crucial for the scientific community to continue investigating more robust markers and treatment options. The review of existing literature and observational studies discussed in the commentary advocates for comprehensive trials that can substantiate the findings concerning SII as a prognostic tool. Only through rigorous testing and validation can healthcare professionals truly understand the implications of SII in diverse patient populations.

Additionally, the researchers highlight the need for a multidisciplinary approach in tackling heart failure. Collaborations across specialties, including cardiology, immunology, and geriatrics, could yield enhanced insights and create holistic treatment plans that address both the cardiac and inflammatory components of HFpEF more effectively.

While this commentary sheds light on the growing importance of the systemic immune-inflammation index, it also opens the door for further inquiry into other biological markers that could provide additional context in the treatment and management of heart failure. The ongoing investigation of these indices will likely reveal a wider array of opportunities for healthcare providers to personalize care for heart failure patients.

In conclusion, the commentary by Shao, Zhu, and Yin offers a thought-provoking perspective on the association between systemic immune-inflammation index and heart failure with preserved ejection fraction. By underscoring the importance of inflammatory markers like SII, it elucidates a critical area within cardiovascular research that merits further exploration. The findings not only bear implications for clinical practice but also advocate for a paradigm shift in how heart failure is conceptualized, diagnosed, and treated within the healthcare landscape.

As we navigate the complexities of cardiovascular health, harnessing the potential of systemic inflammatory markers such as SII may illuminate the path toward more effective interventions. Future studies building upon these insights could bring us a step closer to redefining optimal care strategies for heart failure patients and ultimately reduce the burden of this debilitating condition on our healthcare systems.

By encouraging a broader dialogue about the interplay between inflammation and cardiac function, the authors contribute significantly to our understanding of heart failure and pave the way for future research that could lead to breakthrough therapies. The conversation initiated here is crucial for pushing the boundaries of our knowledge and improving patient outcomes in the realm of cardiovascular medicine.

Subject of Research: The association of systemic immune-inflammation index with adverse outcomes in heart failure and preserved ejection fraction.

Article Title: Comments on “Association of systemic immune-inflammation index with adverse outcomes in heart failure and preserved ejection fraction”.

Article References:

Shao, J., Zhu, C. & Yin, J. Comments on “Association of systemic immune-inflammation index with adverse outcomes in heart failure and preserved ejection fraction”.
J Transl Med 23, 1165 (2025). https://doi.org/10.1186/s12967-025-07339-9

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07339-9

Keywords: systemic immune-inflammation index, heart failure, preserved ejection fraction, inflammation, cardiovascular health, biomarkers, predictive markers, clinical implications.

Sepsis, a critical systemic inflammatory response to infection, often precipitates acute kidney injury (AKI), complicating patient prognosis considerably. At the cellular level, this pathophysiological cascade involves heightened oxidative stress, lipid peroxidation, and programmed cell death subroutines such as ferroptosis—a regulated form of cell demise driven by iron-dependent lipid peroxidation. The intricate interplay between these molecular events disrupts renal cellular homeostasis, escalating tissue damage. Untangling these processes has become imperative for the development of novel interventions that address the root causes, rather than just the symptoms, of sepsis-triggered renal dysfunction.

Central to the new findings is the dual role of radioprotective 105 in modulating oxidative balance and ferroptosis inhibition. Previously characterized for its capacity to shield cells from radiation-induced damage, this compound demonstrates remarkable efficacy in dampening oxidative stress within renal tissues under septic conditions. Its modulatory effects extend to enhancing the expression of heme oxygenase-1 (HO-1), an enzyme known for cytoprotective, antioxidative functions. The upregulation of HO-1 catalyzes the degradation of pro-oxidant heme into biliverdin, carbon monoxide, and free iron, thereby conferring multifaceted cellular defense.

Equally critical in this newly elucidated mechanism is the role of the cystine/glutamate antiporter system Xc−, with SLC7A11 as a key subunit. This transporter maintains intracellular glutathione levels by facilitating cystine import, an amino acid essential for glutathione synthesis. Glutathione, a major antioxidant tripeptide, is indispensable for curbing reactive oxygen species accumulation and lipid peroxidation, effectively impeding ferroptosis. Radioprotective 105’s enhancement of SLC7A11 expression promotes glutathione replenishment, stabilizing cellular redox status amidst septic insult.

Moreover, glutathione peroxidase 4 (GPX4), a selenium-containing enzyme, emerges as the final executor in this protective framework. GPX4 catalyzes the reduction of harmful lipid hydroperoxides to their corresponding alcohols, thwarting ferroptotic death. The research reveals that radioprotective 105 strengthens GPX4 activity, consolidating its blockade against ferroptosis and attenuating renal tubular cell demise. This triad—HO-1 elevation, SLC7A11 upregulation, and GPX4 activation—constitutes a robust defense mechanism that significantly alleviates sepsis-induced renal deterioration.

At the molecular signaling level, radioprotective 105 exerts additional influence over oxidative stress regulators. The compound modulates nuclear factor erythroid 2–related factor 2 (Nrf2) signaling, a master transcription factor governing antioxidant response elements. Activation of Nrf2 by radioprotective 105 potentiates the transcription of HO-1 and SLC7A11 genes, amplifying the cell’s antioxidative capacity. This pathway integration underscores the intricate crosstalk between redox homeostasis and ferroptosis control, positioning radioprotective 105 as a multifaceted modulator.

In vivo experiments further substantiate radioprotective 105’s therapeutic potential. Animal models of sepsis-mediated renal injury subjected to this treatment displayed markedly improved renal function parameters, decreased markers of oxidative damage, and reduced histopathological evidence of tubular necrosis. These phenotypic improvements align with biochemical data illustrating diminished reactive oxygen species and lipid peroxidation levels. Collectively, these findings suggest a promising translational trajectory for clinical application in septic AKI management.

The discovery bears clinical significance as current sepsis therapies largely focus on infection control and supportive measures, lacking specific interventions targeting ferroptosis and oxidative stress pathways. Radioprotective 105, by modulating the HO-1/SLC7A11/GPX4 axis, transcends symptomatic treatment and addresses the pathological sequelae at their molecular origins. This paradigm shift could redefine therapeutic strategies for sepsis-induced organ failure, particularly in the fragile milieu of critically ill patients.

Further exploration reveals potential combinatorial benefits when radioprotective 105 is paired with existing antioxidants or iron chelators. Such synergistic regimens could amplify protective effects, curtailing the vicious cycle of inflammation and oxidative damage characteristic of sepsis. Ongoing research aims to delineate optimal dosing, pharmacodynamics, and safety profiles, paving the way for clinical trials that could establish radioprotective 105 as a cornerstone therapy in intensive care settings.

Interestingly, this study also elucidates the temporal dynamics of ferroptosis in sepsis, noting an early surge in lipid peroxidation followed by progressive antioxidant depletion. Radioprotective 105’s intervention during this critical window effectively rescues renal cells, signifying the importance of timely therapeutic administration. This insight may influence biomarker development for early detection of ferroptosis and stratification of patients who might benefit most from such targeted therapies.

Beyond the kidney, the implications of modulating the HO-1/SLC7A11/GPX4 axis extend to other organs susceptible to septic damage, including the lungs and liver. The conserved nature of oxidative and ferroptotic pathways suggests a broader applicability of radioprotective 105, potentially attenuating multi-organ dysfunction syndrome (MODS), a leading cause of mortality in sepsis. Future multidisciplinary investigations will be key to harnessing the full therapeutic potential of this compound.

At a mechanistic level, the study bridges knowledge gaps between redox biochemistry and cell death modalities in inflammatory diseases. It highlights how ferroptosis is not merely a pathologic consequence but a modifiable process intertwined with cellular antioxidant defenses. Radioprotective 105 emerges as both a probe and a remedy, enabling researchers to dissect and manipulate these pathways with unprecedented specificity.

The research community is optimistic that such insights will catalyze the development of novel pharmacological agents tailored to modulate ferroptosis and oxidative stress with precision, minimizing off-target effects. Radioprotective 105 exemplifies a new class of molecules with targeted action on cellular defense circuits rather than broad-spectrum antioxidants that have shown limited success in clinical trials.

In summary, the study conducted by Duo, Yang, Luo, et al., published in Cell Death Discovery, paves the way for innovative therapeutic interventions in sepsis-associated renal injury. By unraveling the modulatory role of radioprotective 105 on the HO-1/SLC7A11/GPX4 axis, the research offers a beacon of hope for reducing sepsis mortality through targeted molecular therapy. This advancement not only enriches our understanding of ferroptosis regulation but also propels science toward effective clinical solutions against sepsis complications.

As this research progresses from bench to bedside, it heralds a new era in critical care medicine where modulation of cell death pathways becomes an attainable therapeutic goal. Radioprotective 105 stands at the forefront of this movement, promising to transform outcomes for millions affected by sepsis worldwide.

Subject of Research: The modulatory effects of radioprotective 105 on oxidative stress and ferroptosis in sepsis-induced renal injury via the HO-1/SLC7A11/GPX4 signaling axis.

Article Title: Modulatory role of radioprotective 105 in mitigating oxidative stress and ferroptosis via the HO-1/SLC7A11/GPX4 axis in sepsis-mediated renal injury.

Article References:
Duo, H., Yang, Y., Luo, J. et al. Modulatory role of radioprotective 105 in mitigating oxidative stress and ferroptosis via the HO-1/SLC7A11/GPX4 axis in sepsis-mediated renal injury. Cell Death Discov. 11, 290 (2025). https://doi.org/10.1038/s41420-025-02578-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02578-7